Kazia Therapeutics Limited American Depositary Shares (KZIA)

Price$12.56

Value ScoreF

Growth ScoreC

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)54.93%

Price vs S&P 500 (4W)-9.53%

VGM Score48.23

Market Capitalization$103.99M

All Metrics

Book Value / Share (Quarterly)$0.01

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)279.24%

Cash Flow / Share (Quarterly)$-0.00

Price vs S&P 500 (YTD)74.55%

Gross Margin (TTM)77.70%

Net Profit Margin (TTM)-9259.16%

EPS (TTM)$-0.01

10-Day Avg Trading Volume0.22M

EPS Excl Extra (TTM)$-0.01

Revenue Growth (5Y)11.58%

EPS (Annual)$-0.03

ROI (Annual)-147.79%

Gross Margin (Annual)77.60%

Net Profit Margin (5Y Avg)-261385.72%

Cash / Share (Quarterly)$0.01

Revenue Growth QoQ (YoY)461.28%

ROA (Last FY)-341.56%

Revenue Growth TTM (YoY)-89.49%

EBITD / Share (TTM)$-0.01

ROE (5Y Avg)-97.91%

Operating Margin (TTM)-10667.11%

Cash Flow / Share (Annual)$-0.01

P/B Ratio4.34x

P/B Ratio (Quarterly)0.32x

EV / Revenue (TTM)595.74x

Net Interest Coverage (TTM)-77.23x

ROA (TTM)-59.09%

EPS Incl Extra (Annual)$-0.03

Current Ratio (Annual)0.35x

Quick Ratio (Quarterly)2.86x

3-Month Avg Trading Volume0.21M

52-Week Price Return238.10%

Tangible BV / Share (Quarterly)$0.01

P/S Ratio (Annual)1770.89x

Asset Turnover (Annual)0.02x

52-Week High$17.40

Operating Margin (5Y Avg)-265734.98%

EPS Excl Extra (Annual)$-0.03

26-Week Price Return70.86%

Quick Ratio (Annual)0.32x

13-Week Price Return44.41%

Total Debt / Equity (Annual)0.15x

Current Ratio (Quarterly)2.87x

Enterprise Value$105.30M

Revenue / Share Growth (5Y)-25.98%

Asset Turnover (TTM)0.01x

Inventory Turnover (Annual)1.54x

Pretax Margin (Annual)-19691.23%

Cash / Share (Annual)$0.00

3-Month Return Std Dev104.28%

Gross Margin (5Y Avg)70.65%

ROE (Last FY)-169.83%

Net Interest Coverage (Annual)-7.40x

EPS Basic Excl Extra (Annual)$-0.03

Receivables Turnover (TTM)34.73x

Total Debt / Equity (Quarterly)0.31x

EPS Incl Extra (TTM)$-0.01

Receivables Turnover (Annual)7606.56x

ROI (TTM)-20.66%

P/S Ratio (TTM)819.82x

Pretax Margin (5Y Avg)-265457.64%

Revenue / Share (Annual)$0.00

Price vs S&P 500 (52W)209.89%

Year-to-Date Return85.49%

5-Day Price Return-6.44%

EPS Normalized (Annual)$-0.03

ROA (5Y Avg)-124.54%

Net Profit Margin (Annual)-18159.65%

Month-to-Date Return-6.30%

EBITD / Share (Annual)$-0.03

Operating Margin (Annual)-21075.44%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-91.00%

LT Debt / Equity (Quarterly)0.32x

EPS Basic Excl Extra (TTM)$-0.01

P/TBV (Quarterly)0.33x

Inventory Turnover (TTM)1.54x

Pretax Margin (TTM)-9913.15%

Price vs S&P 500 (13W)34.66%

Beta2.20x

P/FCF (Annual)315.44x

Revenue / Share (TTM)$0.00

ROE (TTM)-27.01%

52-Week Low$3.54

vGradeF

gGradeC

mGradeB

vgmGradeC

Show chart for

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.13

4.11

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
KZIAKazia Therapeutics Limited American Depositary Shares	F	C	B	$12.56
LLYEli Lilly & Co.	D	B	B	$1082.20
JNJJohnson & Johnson	C	C	C	$223.51
ABBVABBVIE INC.	D	C	C	$212.93
MRKMerck & Co., Inc.	C	C	C	$115.17
NVSNovartis AG	C	C	C	$145.68
AZNAstraZeneca PLC	D	B	C	$179.71
NVONovo-Nordisk A/S	B	B	C	$44.07
ABTAbbott Laboratories	C	C	D	$87.78
PFEPfizer Inc.	B	C	C	$25.63
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$34.64

About

Kazia Therapeutics is an oncology-focused biotechnology company developing targeted cancer therapies. Its lead program, Paxalisib, is an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway designed to treat brain cancers. The company maintains operations in Australia and the United States and has a portfolio of additional development candidates across various cancer indications.